Genuit Share Discussion Threads

[rambutan2] 23/12/2005 00:09

and jonwig has started a thread...

[elgordo] 22/12/2005 09:09

In case anyone is interested, CMR Fuel Cells is trading under the EPIC code of CMF - opened in high 190's, now drifted down a little to just above 190.

[kdwilson] 22/12/2005 07:47

11% of £35m is £3.6m versus a few hundred grand booked on the balance sheet. This should add 3p at least to NAV before any appreciation of CRM. Time to fill boots if this doesnt fly immediately.

[maytrees] 19/12/2005 08:49

Indy comments today:
"...awards fuels interest in CMR

CMR Fuel Cells, which claims to have developed a revolutionary type of fuel cell technology, will debut on AIM this week. Investec Securities, the group's broker, has had little trouble raising money for the company. In fact, it was forced to increase the size of the fund raising from £8m to £10-12m because of investor demand. This will value the company at about £35m.

CMR, founded by Michael Priestnall and Michael Evans, has developed a fuel cell which converts methanol into electricity. To start with, the group plans to target the consumer electronics markets where existing batteries are struggling to produce the performance increasingly required by users of mobile phones and laptops. CMR says its fuel cells can produce more power than anything currently available of that size.

The group has picked up an impressive array of awards over the past year. These have included the 2005 Carbon Trust Overall Innovator of the Year award and the Carbon Trust Small Business award. It was also named by Harvard Business School as one of the 25 companies most likely to change the world by 2010. CMR is definitely one for investors to keep an eye on in the months after its float."

I hold gen - dyor

[elgordo] 16/12/2005 11:25

Thanks rambutan2. I see they are raised more than originally suggested (£10.3m rather than £8m).

With 20,304,846 shares to be issued at a price of 176p, that's a market capitalisation of £35.7m, of which Generics' 11% stake will be £3.9m (or 1.8p per Generics share).

In reality, not a huge boost to Generics' net worth, but I would agree with kdwilson that the main impacts here will be a boost to Generics' profile and a validation of their ability to build value from their portfolio.

[rambutan2] 16/12/2005 10:52

cmr listing details. due to list next tues. post admission, gen are interested in 11%...

[adejuk] 14/12/2005 21:10

Prospective Students
Students & Staff
Business
Alumni
Visitors

Information on...
The University
Schools & Departments
Courses
Research
News & Events
Helen Meadows. Public Relations Manager,
Cranfield University,
Cranfield
Bedfordshire.
MK43 0AL.
Tel: [phone]. Fax: [phone].
Email: [e-mail]


Issue Date: Tuesday 15 July, 2003
Release Date: Tuesday 15 July, 2003

CRANFIELD MOVES IN A NEW SPHERE
As part of its ever-increasing involvement with the sharp end of the commercial sector, Cranfield University has signed a deal with Sphere Medical Ltd to jointly exploit Cranfield's extensive Molecularly Imprinted Polymer (MIP) patent portfolio in the field of clinical diagnostics.

MIPs are an emerging class of receptors that mimic the selective properties of biomolecules like antibodies and enzymes but are made from plastic. Hence, MIPs avoid many of the shortcomings associated the use of biomolecules in diagnostics such as stability and cost. The ability to tailor the properties of MIPs to the exact requirements of any particular system means that sensors which were previously impossible or impractical to produce by conventional means will become a commercial reality.

Professor Tony Turner, Head of Cranfield University at Silsoe reports, "These new synthetic receptors herald a step change in the diagnostics industry and Cranfield is pleased to have secured a partner who can rapidly realise the potential of this leading edge science. Cranfield's renowned twin strengths of cutting edge technology and commercial awareness have been the bedrock of this growing relationship. I foresee this as the first of many such commercial ventures, partnerships and liaisons in this field that I will be able to announce in the very near future"

Sphere Medical Ltd, based in Cambridge, develops and manufactures microsensors for use in the medical devices industry. Exploiting recent developments in MST (Microsystem Technology) and nanotechnology, Sphere's current product portfolio includes sensors to measure clinically important parameters such as oxygen and carbon dioxide as well as metabolites like glucose and lactate. It has established a number of relationships with global players to supply its technology into a variety of clinical applications.

The use of MIPs in conjunction with Sphere's proprietary microsensor technology will form a new benchmark of miniature, cheap and robust, diagnostic devices with the potential to revolutionise clinical practice.

Dr Stuart Hendry, CEO of Sphere Medical and Cranfield alumnus said, "We are delighted to have signed this deal with a world-leading institution such as Cranfield gaining access to such powerful technology; we are convinced that this will be a long and productive relationship."

Ends

Back Press release home




Top of Page Published by Marketing & Communication. © Cranfield University.

[kdwilson] 12/12/2005 11:40

I guess that the key impact of this near-term will be to raise GEN's profile. CRM will be seeing lots of institutions who will then also look at GEN. This will lead to interest in other spin offs etc. Still think 20p by March next year possible.

[elgordo] 12/12/2005 11:22

The FT article suggests that Generics will retain a 12% stake, and CMR will be valued at around £30m. This gives Generics' holding an estimated value of £3.6m, against the £0.8m currently, which is an uplift of £2.8m. With around 215m shares in issue, this equates to an extra 1.3p per share on the value of Generics.

Something else of interest in the FT article is that CMR does not intend to license its technology, but rather outsource its production. This is a higher risk/higher reward strategy, in that if they really are on to a winning technology they will get the revenues directly, rather than taking a cut of the licensees' revenues, but will have to stump up the development and production costs alone.

The fact that that they are taking this route suggests to me either huge confidence in the technology, a gung ho attitude to risk, or that they haven't had any interest from possible licensees. Let's hope it turns out to be the first of these!

One final bit of information from the FT article - they expect to go into production in 2008. This isn't that far off, but it does occur to me that if they are not going to out-license, they could be in for a pretty RNS-free couple of years, which might not be good for the share price of a "jam tomorrow" company.

[kdwilson] 12/12/2005 09:46

i think 12-13%

[rambutan2] 12/12/2005 09:19

we currently hold 16% of cmr. wonder what it will be diluted down to after fundraising?

[kdwilson] 12/12/2005 07:57

see page 22 of FT - The new non exec Chairman is also subscribing for £1m - that's a major endorsment of CRM. Gen could have something big on its hands...assuming CRM is as good as it looks, the market cap could easily be well north of £60m within 12 months. This on its own means Gen should be worth over 18p...before its other spin offs come to market! Silly price below 15p in my view!

[rambutan2] 10/12/2005 17:55

i was quite enjoying your ramblings elgordo!

[elgordo] 10/12/2005 17:23

In the unlikely event that anyone is taking any notice of my ramblings about CMR, I should point out a mistake in my post 417 above. The £250,000 figure was the amount Generics put into the Series B funding, out of a rather more substantial total of £2.3m. Whilst this makes the £8m being sought now rather more credible, it does still suggest a significant increase in scale over such a short period.

I'll try and shut up about this now, at least until more information on the float is published.

[elgordo] 09/12/2005 19:56

On reflection, why would a company only valued at £4.6m (post Series B funding) five months ago expect to be able to raise new funds of £8m now, unless they have some pretty substantial news they can release as part of the fundraising? I may be wrong, but it seems to me that we should expect a significant announcement from CMR in the next few days, to support their floatation and fundraising plans.

[elgordo] 08/12/2005 11:51

From the prelims, Generics had a 17.5% stake in CMR valued at £0.8m, valuing the company as a whole at £4.6m. This followed a Series B funding of just £250k in July '05. The fact that they are looking to raise £8m only five months later as part of their listing suggests a step change in the business model.

[elgordo] 08/12/2005 10:20

Blimey - good spot. Here's the same news with a few more words, but no extra information (like, for, example, what they are valuing the company at on listing...)

[humpja] 08/12/2005 10:06

Nothing on the CMR website though.

[kdwilson] 05/12/2005 18:15

this thing can double quickly when some of their private companies IPO over the next few months....NAV can easily get up to 20p!!

[rambutan2] 05/12/2005 10:01

big sigh of relief...

"The order book and sales processes are now strong enough to
sustain the ongoing growth and profitability in the technology consulting
business, which is central to the health of the overall Group."

it's been a long time coming!

[kdwilson] 05/12/2005 07:21

cracking set of Q3 results - this little company is on a roll and massively undervalued. Once teh City picks up on this i suspect 20p/shares will duly follow!!. A steal down here at 12p!!

[kdwilson] 28/11/2005 12:50

that;s good news...i also suspect we'll get some positive news on IPOs shortly...this could be the final twitch by MM to collect up stock....the recent jump in teh shares was clearly a large buyer...id expect more to emerge as the true value of gen's assets starts to get highlighted to the market in the immediate future...i'm looking for 20p

[maxwellsdemon] 28/11/2005 07:39

New patent application just published a feww days ago:

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(11) WO 2005/111551
(13) A1


(21) PCT/GB2005/001863

(22) 16 May 2005 (16.05.2005)

(25) English
(26) English

(30) 0410845.2 14 May 2004
(14.05.2004) GB
0412978.9 11 June 2004
(11.06.2004) GB
0413182.7 12 June 2004
(12.06.2004) GB
(43) 24 November 2005 (24.11.2005)
(51)7 G01F 23/26
(54) CAPACITIVE POSITION SENSOR
(71) SCIENTIFIC GENERICS LTD. [GB/GB]; Harston Mill, Harston, Cambridge CB2 5GG (GB).
(72)
(75) ZHITOMIRSKY, Victor, Evgenievich [RU/GB]; C/O Scientific Generics Ltd., Harston Mill, Harston, Cambridge CB2 5GG (GB).
(74) I.P. 21 LIMITED; Norwich Research Park, Colney, Norwich, NR4 7UT (GB).
(81) AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
(84) ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

For information on time limits for entry into the national phase please click here
Published
-- with international search report
-- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments


(57) A capacitive position sensor has a periodic array of electrodes (12, 14, 16, 18) which form capacitors between pairs of the electrodes. The location of a dielectric inhomogeneity in the vicinity of the sensor is determined by comparison of the relative change in the capacitance of the capacitors. The comparison may be carried out using a capacitive Wheatstone Bridge arrangement. The sensor configuration has the advantage that it is independent of the absolute value of the dielectric constant of the environment in which the sensor is located.

[kdwilson] 11/11/2005 08:06

either a large buyer, or v bullish note out, or more spin offs in the pipeline....whatever it is, buying below NAV is going to prove a great call on a 6 month view!!

[rambutan2] 10/11/2005 02:12

well, that's a good sign.